Evaluation of IBI302 Injection in nAMD or DME
A Dose Escalation Study to Evaluate the Safety and Tolerability of IBI302 Intravitreal Injection in Subjects With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema AND A Multi-center, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With Diabetic Macular Edema
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Suspended
Company strategy adjustment
A PHASE1/PHASE2 clinical study on Diabetic Macular Edema and Neovascular Age-related Macular Degeneration, this trial is suspended. The trial is conducted by Innovent Biologics (Suzhou) Co. Ltd. and has accumulated 3 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
3 versions recorded-
Sep 2024 — Present [monthly]
Suspended PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Suspended PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Aug 2023 — Jul 2024 [monthly]
Suspended PHASE1_PHASE2
First recorded
Nov 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Innovent Biologics (Suzhou) Co. Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .